• 1. González-García R, Naval-Gías L, Martos PL. Melanoma of the oral mucosa. Clinical cases and review of the literature. Med Oral Patol Oral Cir Bucal 2005; 10: 264271.

    • Search Google Scholar
    • Export Citation
  • 2. Tanaka N, Mimura M, Ogi K, et al. Primary malignant melanoma of the oral cavity: assessment of outcome from the clinical records of 35 patients. Int J Oral Maxillofac Surg 2004; 33: 761765.

    • Search Google Scholar
    • Export Citation
  • 3. Liptak JM, Withrow SJ. Cancer of the gastrointestinal tract. In: Small animal clinical oncology. St Louis: Saunders, 2007; 455475.

  • 4. Liptak JM, Lascelles BX. Oral tumors. In: Kudnig ST, Séguin B, eds. Veterinary surgical oncology. Ames, Iowa: Wiley Blackwell, 2012;119178.

    • Search Google Scholar
    • Export Citation
  • 5. Murphy S, Hayes AM, Blackwood L, et al. Oral malignant melanoma—the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol 2005; 3: 222229.

    • Search Google Scholar
    • Export Citation
  • 6. Blackwood L, Dobson JM. Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc 1996; 209: 98102.

  • 7. Proulx DR, Ruslander DM, Dodge RK, et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound 2003; 44: 352359.

    • Search Google Scholar
    • Export Citation
  • 8. Brockley LK, Cooper MA, Bennett PF. Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatin chemotherapy on survival. N Z Vet J 2013; 61: 2531.

    • Search Google Scholar
    • Export Citation
  • 9. Dank G, Rassnick KM, Sokolovsky Y, et al. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Vet Comp Oncol 2014; 12: 7884.

    • Search Google Scholar
    • Export Citation
  • 10. Taylor KH, Smith AN, Higginbotham M, et al. Expression of vascular endothelial growth factor in canine oral malignant melanoma. Vet Comp Oncol 2007; 5: 208218.

    • Search Google Scholar
    • Export Citation
  • 11. USDA licenses DNA vaccine for treatment of melanoma in dogs. J Am Vet Med Assoc 2010; 236: 495.

  • 12. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 12841290.

    • Search Google Scholar
    • Export Citation
  • 13. Grosenbaugh DA, Leard AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011; 72: 16311638.

    • Search Google Scholar
    • Export Citation
  • 14. Ottnod JM, Smedley RC, Walshaw R, et al. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet Comp Oncol 2013; 11: 219229.

    • Search Google Scholar
    • Export Citation
  • 15. Smedley RC, Spangler WL, Esplin DG, et al. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. Vet Pathol 2011; 48: 5472.

    • Search Google Scholar
    • Export Citation
  • 16. Williams LE, Packer RA. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987–2001). J Am Vet Med Assoc 2003; 222: 12341236.

    • Search Google Scholar
    • Export Citation
  • 17. Suton P, Lukšić I, Müller D, et al. Lymphatic drainage patterns of head and neck cutaneous melanoma: does primary melanoma site correlate with anatomic distribution of pathologically involved lymph nodes? Int J Oral Maxillofac Surg 2012; 41: 413420.

    • Search Google Scholar
    • Export Citation
  • 18. Sun CZ, Chen YF, Jiang YE, et al. Treatment and prognosis of oral mucosal melanoma. Oral Oncol 2012; 48: 647652.

  • 19. Bodem JP, Gülicher D, Engel M, et al. Role of neck dissection in the treatment of melanoma of the head and neck. J Craniofac Surg 2013; 24: 483487.

    • Search Google Scholar
    • Export Citation
  • 20. Hahn KA, DeNicola DB, Richardson RC, et al. Canine oral malignant melanoma: prognostic utility of an alternative staging system. J Small Anim Pract 1994; 35: 251256.

    • Search Google Scholar
    • Export Citation
  • 21. Bast RC, Kufe DW, Pollock RE, et al. Principles of surgical oncology. In: Holland JC, Frei E, eds. Cancer medicine. 5th ed. Hamilton, ON, Canada: BC Decker, 2000.

    • Search Google Scholar
    • Export Citation

Advertisement

Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001–2012)

View More View Less
  • 1 Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32608.
  • | 2 Department of Biostatistics and Children's Oncology Group, College of Public Health and Health Professions and Medicine, University of Florida, Gainesville, FL 32608.
  • | 3 Department of Veterinary Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.
  • | 4 Clinica Veterinaria Nerviano, Via Giulio Cesare Lampugnani, Nerviano, MI 320014, Italy.
  • | 5 Clinica Veterinaria Nerviano, Via Giulio Cesare Lampugnani, Nerviano, MI 320014, Italy.
  • | 6 MedVet Columbus, Medical and Cancer Centers for Pets, 300 E Wilson Bridge Rd, Worthington, OH 43085.
  • | 7 Alta Vista Animal Hospital, 2616 Bank St, Ottawa, ON K1T 1M9, Canada.
  • | 8 Center for Research in Veterinary Sciences, Faculty of Veterinary Medicine, Lusofona University, Lisbon, Portugal.
  • | 9 Dipartimento di Scienze Veterinarie, University of Turin, Torino, 10095, Italy.

Abstract

Objective—To determine prognostic factors for and compare outcome among dogs with oral malignant melanoma following excision with or without various systemic adjuvant therapies.

Design—Retrospective case series.

Animals—151 dogs with naturally occurring oral malignant melanomas treated by excision with or without adjuvant therapies from 2001 to 2012.

Procedures—Case accrual was solicited from Veterinary Society of Surgical Oncology members via an email list service. Information collected from case records included signalment, tumor staging, tumor characteristics, type of surgical excision, histologic diagnosis, adjuvant therapy, and survival time.

Results—The overall median survival time was 346 days. Results of multivariate analysis indicated that tumor size, patient age, and intralesional excision (vs marginal, wide, or radical excision) were considered poor prognostic indicators. All other demographic and clinical variables were not significantly associated with survival time after adjusting for the aforementioned 3 variables. A clear survival benefit was not evident with any systemic adjuvant therapy, including vaccination against melanoma or chemotherapy; however, the number of dogs in each treatment group was small. Ninety-eight dogs received no postoperative adjuvant therapy, and there was no difference in survival time between dogs that did (335 days) and did not (352 days) receive systemic adjuvant therapy.

Conclusions and Clinical Relevance—For dogs with oral malignant melanoma, increasing tumor size and age were negative prognostic factors. Complete excision of all macroscopic tumor burden improved survival time. Long-term survival was possible following surgery alone. Although systemic adjuvant therapy was not found to improve survival time, this could have been due to type II error.

Contributor Notes

Supported by the Veterinary Society of Surgical Oncology Research Committee.

Address correspondence to Dr. Boston (sboston@ufl.edu).